Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.

被引：1
|
作者：
Ahluwalia, Manmeet Singh
Reardon, David A.
Abad, Ajay P.
Curry, William T.
Wong, Eric T.
Belal, Ahmed
Qiu, Jingxin
Mogensen, Kathleen
Schilero, Cathy
Casucci, Danielle
Mechtler, Laszlo
Uhlmann, Erik J.
Ciesielski, Michael J.
Fenstermaker, Robert
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
[6] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[7] Roswell Pk Canc Inst, Buffalo, NY USA
[8] Dent Neurol Inst, Buffalo, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2041
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2041
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.
    Ahluwalia, Manmeet Singh
    Reardon, David A.
    Abad, Ajay P.
    Curry, William T.
    Wong, Eric T.
    Belal, Ahmed
    Qiu, Jingxin
    Mogensen, Kathleen
    Schilero, Cathy
    Hutson, Alan
    Casucci, Danielle
    Mechtler, Laszlo
    Uhlmann, Erik J.
    Ciesielski, Michael J.
    Fenstermaker, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) FOR NEWLY DIAGNOSED GLIOBLASTOMA
    Ahluwalia, Manmeet
    Reardon, David
    Abad, Ajay
    Curry, William
    Wong, Eric
    Peereboom, David
    Belal, Ahmed
    Qiu, Jingxin
    Mogensen, Kathleen
    Schilero, Cathy
    Casucci, Danielle
    Mechtler, Laszlo
    Uhlmann, Erik
    Ciesielski, Michael
    Fenstermaker, Robert
    NEURO-ONCOLOGY, 2018, 20 : 10 - 11
  • [3] PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
    Ahluwalia, Manmeet
    Ciesielski, Michael J.
    Reardon, David A.
    Abad, Ajay
    Curry, William
    Wong, Eric
    Peereboom, David
    Figel, Sheila
    Hutson, Alan
    Groman, Adrienne
    Withers, Henry
    Liu, Song
    Belal, Ahmed
    Qiu, Jingxin
    Mogensen, Kathleen
    Schilero, Cathy
    Khosla, Atulya
    Casucci, Danielle
    Mechtler, Laszlo
    Fenstermaker, Robert
    NEURO-ONCOLOGY, 2022, 24 : 66 - 66
  • [4] Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma.
    Molaie, Donna
    Lai, Albert
    Ellingson, Benjamin M.
    Thien Nguyen
    Bahng, Hye Hyun
    Filka, Emese
    Green, Stacey
    Pope, Whitney B.
    Leng, Mei
    Yong, William H.
    Green, Richard M.
    Polikoff, Jonathan
    Spier, Liz
    Iwamoto, Fabio Massaiti
    Lassman, Andrew B.
    Cloughesy, Timothy Francis
    Nghiemphu, Phioanh Leia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Phase II trial of bevacizumab and temozolomide for upfront treatment of elderly patients with newly diagnosed glioblastoma.
    Nghiemphu, Phioanh Leia
    Bahng, Hye Hyun
    Lai, Albert
    Faiq, Nadia
    Yong, William H.
    Green, Richard M.
    Polikoff, Jonathan
    Spier, Cynthia Elizabeth
    Iwamoto, Fabio Massaiti
    Lassman, Andrew B.
    Cloughesy, Timothy Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
    Chinot, O. L.
    Wick, W.
    Saran, F.
    Mason, W. P.
    Henriksson, R.
    Nishikawa, R.
    Zeaiter, A. H.
    Moore, N.
    Das, A.
    Cloughesy, T. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial
    Grossman, Stuart A.
    Ye, Xiaobu
    Chamberlain, Marc
    Mikkelsen, Tom
    Batchelor, Tracy
    Desideri, Serena
    Piantadosi, Steven
    Fisher, Joy
    Fine, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : 4155 - 4161
  • [8] A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.
    Odia, Yazmin
    Goldlust, Samuel Aaron
    Mehta, Minesh P.
    Lassman, Andrew B.
    Colman, Howard
    Kumthekar, Priya
    Mason, Warren P.
    Harrison, Rebecca A.
    Butowski, Nicholas A.
    Venur, Vyshak
    Plotkin, Scott Randall
    Schulder, Michael
    Boockvar, John A.
    Duic, J. Paul
    Li, Kai
    Liu, Yang
    Tamir, Sharon
    Mundy, Gregory
    Shacham, Sharon
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] A PHASE IB TRIAL OF CEDIRANIB IN ADDITION TO STANDARD TEMOZOLOMIDE AND RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Chi, Andrew S.
    Gerstner, Elisabeth R.
    Eichler, April F.
    Chea, Houng K.
    Shearer, Nancy
    Drappatz, Jan
    Wen, Patrick Y.
    Ivy, S. Percy
    Loeffler, Jay S.
    Sorensen, A. Gregory
    Jain, Rakesh K.
    Batchelor, Tracy T.
    NEURO-ONCOLOGY, 2009, 11 (06) : 946 - 947
  • [10] PROSPECTIVE RANDOMIZED PHASE II PLACEBO-CONTROLLED TRIAL OF SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA (SURVIVE)
    Ahluwalia, Manmeet
    Ciesielski, Michael J.
    Abad, Ajay
    Reardon, David A.
    Aiken, Robert
    Barbaro, Marissa
    Sinicrope, Kaylyn
    Peereboom, David
    Odia, Yazmin
    Brenner, Andrew
    Venur, Vyshak
    Belal, Ahmed
    Qiu, Jingxin
    Khosla, Atulya
    Schilero, Cathy
    Casucci, Danielle
    Mechtler, Laszlo
    Fenstermaker, Robert
    NEURO-ONCOLOGY, 2022, 24 : 64 - 64
12345